Multi-Cancer Early Detection Technologies
Resources and Additional Reading

Resource	Address
Ahlquist DA. Universal cancer screening: Revolutionary, rational, and realizable. *NPJ Precis Oncol.* 2018;2:23.	https://pubmed.ncbi.nlm.nih.gov/30393772/
Aravanis AA, Oxnard GR, Maddala T, et al. Abstract LB-343: Development of plasma cell-free DNA (cfDNA) assays for early cancer detection: First insights from the Circulating Cell-Free Genome Atlas study (CCGA). *Cancer Res*. 2018;78(13suppl):LB-343.	https://aacrjournals.org/cancerres/article/78/13_Supplement/LB-343/631347/Abstract-LB-343-Development-of-plasma-cell-free
Aravanis AM, Lee M, Klausner RD. Next-generation sequencing of circulating tumor DNA for early cancer detection. *Cell.* 2017;168:571-574.	https://pubmed.ncbi.nlm.nih.gov/28187279/
Barefoot ME, Loyfer N, Kiliti AJ, et al. Detection of cell types contributing to cancer from circulating, cell-free methylated DNA. *Front Genet*. 2021;12:671057.	https://pubmed.ncbi.nlm.nih.gov/34386036/
Brito-Rocha T, Constâncio V, Henrique R, Jerónimo C. Shifting the cancer screening paradigm: The rising potential of blood-based multi-cancer early detection tests. *Cells*. 2023;12:935.	https://pubmed.ncbi.nlm.nih.gov/36980276/
Etzioni R, Gulati R, Weiss NS. Multicancer early detection: Learning from the past to meet the future. *J Natl Cancer Inst*. 2022;114:349-352.	https://pubmed.ncbi.nlm.nih.gov/34450655/
García-Pardo M, Makarem M, Li JJN, et al. Integrating circulating-free DNA (cfDNA) analysis into clinical practice: Opportunities and challenges. *Br J Cancer*. 2022;127:592-602.	https://pubmed.ncbi.nlm.nih.gov/35347327/
Gelhorn H, Ross MM, Kansal AR, et al. Patient preferences for multi-cancer early detection (MCED) screening tests. *Patient*. 2023;16:43-56.	https://pubmed.ncbi.nlm.nih.gov/35844011/
Ignatiadis M, Sledge GW, Jeffrey SS. Liquid biopsy enters the clinic - implementation issues and future challenges. *Nat Rev Clin Oncol.* 2021;18:297-312.	https://pubmed.ncbi.nlm.nih.gov/33473219/
Lawler M, Alsina D, Adams RA, et al. Critical research gaps and recommendations to inform research prioritization for more effective prevention and improved outcomes in colorectal cancer. *Gut.* 2018;67:179-193.	https://pubmed.ncbi.nlm.nih.gov/29233930/
Loomans-Kropp HA, Umar A, Minasian LM, Pinsky PF. Multi-cancer early detection tests: Current progress and future perspectives. *Cancer Epidemiol Biomarkers Prev*. 2022;31:512-514.	https://pubmed.ncbi.nlm.nih.gov/35253043/
Luo H, Wei W, Ye Z, Zheng J, Xu RH. Liquid biopsy of methylation biomarkers in cell-free DNA. *Trends Mol Med*. 2021;27:482-500.	https://pubmed.ncbi.nlm.nih.gov/33500194/

Oxnard GR, Klein EA, Seiden M, et al. Simultaneous multi-cancer detection and tissue of origin (TOO) localization using targeted bisulfite sequencing of plasma cell-free DNA (cfDNA). *J Glob Oncol*. 2019;(5 suppl):44.	https://ascopubs.org/doi/abs/10.1200/JGO.2019.5.suppl.44
Ranucci R. Cell-free DNA: Applications in different diseases. *Methods Mol Biol*. 2019;1909:3-12.	https://pubmed.ncbi.nlm.nih.gov/30580419/
Razavi P, Li BT, Brown DN, et al. High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants. *Nat Med.* 2019;25:1928-1937.	https://pubmed.ncbi.nlm.nih.gov/31768066/
Smith RA, Andrews KS, Brooks D, et al. Cancer screening in the United States, 2019: A review of current American Cancer Society guidelines and current issues in cancer screening. *CA Cancer J Clin.* 2019;69:184-210.	https://pubmed.ncbi.nlm.nih.gov/30875085/
Song P, Wu LR, Yan YH. Limitations and opportunities of technologies for the analysis of cell-free DNA in cancer diagnostics. *Nat Biomed Eng.* 2022;6:232-245.	https://pubmed.ncbi.nlm.nih.gov/35102279/
Stroun M, Maurice P, Vasioukhin V, et al. The origin and mechanism of circulating DNA. *Ann N Y Acad Sci.* 2000;906:161-168.	https://pubmed.ncbi.nlm.nih.gov/10818614/
Tang WHW, Yimer H, Tummala M, et al. Performance of a targeted methylation-based multi-cancer early detection test by race and ethnicity. *Prev Med.* 2023;167:107384.	https://pubmed.ncbi.nlm.nih.gov/36495927/
Ulrich BC, Paweletz CP. Cell-free DNA in oncology: Gearing up for clinic. *Ann Lab Med.* 2018;38:1-8.	https://pubmed.ncbi.nlm.nih.gov/29071812/
Wolpin BM, Richards DA, Cohn AL, et al. Performance of a blood-based test for the detection of multiple cancer types. *J Clin Oncol*. 2020;38(4_suppl):283.	https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.4_suppl.283
Yan, YY, Guo QR, Wang FH, et al. Cell-free DNA: Hope and potential application in cancer. *Front Cell Dev Biol.* 2021;9:639233.	https://pubmed.ncbi.nlm.nih.gov/33693004/
Zhou H, Zhu L, Song J, et al. Liquid biopsy at the frontier of detection, prognosis and progression monitoring in colorectal cancer. *Mol Cancer.* 2022;21:86.	https://pubmed.ncbi.nlm.nih.gov/35337361/

Resources and Societies

Resource	Address
American Association for Cancer Research (AACR)	https://www.aacr.org/
American Academy of Family Physicians (AAFP)	https://www.aafp.org/home.html
American Cancer Society (ACS)	https://www.cancer.org/
American Society of Clinical Oncology (ASCO)	https://www.asco.org/
National Cancer Institute	https://www.cancer.gov/
National Comprehensive Cancer Network® – NCCN Guidelines	https://www.nccn.org/professionals/physician_gls/default.aspx

All URLs accessed 7/19/23